ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
127.308,80
-0,95%
S&P 500
6.144,15
0,24%
US Dollar vs BRL
5,7215
0,55%
Bitcoin
96.452,58
0,93%
Brent Oil
75,815
0,43%
As Melhores Corretoras Online
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. AN2 Therapeutics Inc (ANTX)

  7. AN2 Therapeutics Inc (ANTX) Notícias

ANTX

AN2 Therapeutics (ANTX)

AN2 Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ANTX
DataHoraFonteTítuloCódigoCompanhia
14/02/202518:30Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ANTXAN2 Therapeutics Inc
29/01/202518:00Business WireAN2 Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceNASDAQ:ANTXAN2 Therapeutics Inc
07/01/202522:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
14/11/202409:00Business WireAN2 Therapeutics to Participate at Upcoming Investor ConferencesNASDAQ:ANTXAN2 Therapeutics Inc
13/11/202418:04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANTXAN2 Therapeutics Inc
13/11/202418:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANTXAN2 Therapeutics Inc
13/11/202418:00Business WireAN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry PipelineNASDAQ:ANTXAN2 Therapeutics Inc
05/11/202418:49Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
17/10/202408:00Business WireAN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and MalariaNASDAQ:ANTXAN2 Therapeutics Inc
28/08/202417:00Business WireAN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:ANTXAN2 Therapeutics Inc
19/08/202407:07Edgar (US Regulatory)Form 8-A12B - Registration of securities [Section 12(b)]NASDAQ:ANTXAN2 Therapeutics Inc
16/08/202408:00Business WireAN2 Therapeutics Adopts Limited Duration Stockholder Rights PlanNASDAQ:ANTXAN2 Therapeutics Inc
13/08/202417:01Business WireAN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific HighlightsNASDAQ:ANTXAN2 Therapeutics Inc
08/08/202417:30Business WireAN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung DiseaseNASDAQ:ANTXAN2 Therapeutics Inc
14/05/202417:01Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:ANTXAN2 Therapeutics Inc
14/05/202417:01Business WireAN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific HighlightsNASDAQ:ANTXAN2 Therapeutics Inc
28/03/202417:10Business WireAN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific HighlightsNASDAQ:ANTXAN2 Therapeutics Inc
13/02/202419:11Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ANTXAN2 Therapeutics Inc
12/02/202408:45Business WireAN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung DiseaseNASDAQ:ANTXAN2 Therapeutics Inc
30/01/202418:10Business WireAN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences ConferenceNASDAQ:ANTXAN2 Therapeutics Inc
02/01/202418:45Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ANTXAN2 Therapeutics Inc
09/11/202318:05Business WireAN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific HighlightsNASDAQ:ANTXAN2 Therapeutics Inc
06/11/202309:00Business WireAN2 Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:ANTXAN2 Therapeutics Inc
18/10/202308:00Business WireAN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas DiseaseNASDAQ:ANTXAN2 Therapeutics Inc
11/10/202301:01Business WireAN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023NASDAQ:ANTXAN2 Therapeutics Inc
26/09/202308:00Business WireAN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and MalariaNASDAQ:ANTXAN2 Therapeutics Inc
13/09/202308:00Business WireAN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung DiseaseNASDAQ:ANTXAN2 Therapeutics Inc
16/08/202317:50Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ANTXAN2 Therapeutics Inc
15/08/202323:42Business WireAN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common StockNASDAQ:ANTXAN2 Therapeutics Inc
10/08/202317:10Business WireAN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent HighlightsNASDAQ:ANTXAN2 Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ANTX

Seu Histórico Recente

TG
JY0
ParTec
AQSE
EO.P
ESO EPIC Private Equity
USOTC
SMEGF
Siemens Energy (PK)
BOV
CEBR5R
CEB PNA
BIT
UC8FRF
Unicredit Bank
BIT
UC8XWE
Unicredit Bank
USOTC
WOAM
World Am (CE)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios